A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations

[1]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.

[2]  J. Danesh,et al.  Major lipids, apolipoproteins, and risk of vascular disease. , 2009, JAMA.

[3]  M. V. Es,et al.  Alzheimer’s disease beyond APOE , 2009, Nature Genetics.

[4]  L. Kiemeney,et al.  Corrigendum: Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[5]  Ariadna Besga,et al.  Plasma levels of 24S-hydroxycholesterol reflect brain volumes in patients without objective cognitive impairment but not in those with Alzheimer's disease , 2009, Neuroscience Letters.

[6]  Nick C Fox,et al.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease, and shows evidence for additional susceptibility genes , 2009, Nature Genetics.

[7]  P. Bosco,et al.  Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease , 2009, Nature Genetics.

[8]  M. Bullido,et al.  A free radical‐generating system induces the cholesterol biosynthesis pathway: a role in Alzheimer's disease , 2009, Aging cell.

[9]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[10]  M. Pangalos,et al.  Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels , 2008, The Journal of Neuroscience.

[11]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[12]  T. Hartmann,et al.  Alzheimer’s disease: the lipid connection , 2007, Journal of neurochemistry.

[13]  O. Combarros,et al.  Meta‐analysis of genetic variability in the β‐amyloid production, aggregation and degradation metabolic pathways and the risk of Alzheimer’s disease , 2007, Acta neurologica Scandinavica.

[14]  B. Winblad,et al.  Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE , 2007, Neurobiology of Aging.

[15]  Tatsuhiko Kodama,et al.  Alzheimer's Disease: cholesterol, membrane rafts, isoprenoids and statins , 2007, Journal of cellular and molecular medicine.

[16]  M. Franceschi,et al.  The hydroxy-methyl-glutaryl CoA reductase promoter polymorphism is associated with Alzheimer's risk and cognitive deterioration , 2007, Neuroscience Letters.

[17]  H. Soininen,et al.  Serum cholesterol changes after midlife and late-life cognition , 2007, Neurology.

[18]  Brad E. Pfeiffer,et al.  Brain cholesterol turnover required for geranylgeraniol production and learning in mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Soininen,et al.  Association of CYP46 intron 2 polymorphism in Finnish Alzheimer’s disease samples and a global scale summary , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[20]  Lewis H Kuller,et al.  Statin use and the risk of incident dementia: the Cardiovascular Health Study. , 2005, Archives of neurology.

[21]  M. M. Mielke,et al.  High total cholesterol levels in late life associated with a reduced risk of dementia , 2005, Neurology.

[22]  R. Hennekam.  Congenital brain anomalies in distal cholesterol biosynthesis defects , 2005, Journal of Inherited Metabolic Disease.

[23]  R. Tanzi,et al.  Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.

[24]  D. Sparks,et al.  Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. , 2005, Archives of general psychiatry.

[25]  B. Hyman,et al.  Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer’s disease , 2004, Neuroscience Letters.

[26]  David Posada,et al.  Pharmacogenetic Study of Statin Therapy and Cholesterol Reduction , 2004 .

[27]  Johan Berglund,et al.  A longitudinal study integrating population, care and social services data. The Swedish National study on Aging and Care (SNAC) , 2004, Aging clinical and experimental research.

[28]  L. Feuk,et al.  Variants of CYP46A1 may interact with age and APOE to influence CSF Aβ42 levels in Alzheimer’s disease , 2004, Human Genetics.

[29]  Jay D. Horton,et al.  Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Qiang Xu,et al.  Secretion of apolipoprotein E by brain glia requires protein prenylation and is suppressed by statins , 2002, Brain Research.

[31]  S. DeKosky,et al.  Genetic variation in the cholesterol 24-hydroxylase (CYP46) gene and the risk of Alzheimer's disease , 2002, Neuroscience Letters.

[32]  V. Mooser,et al.  The APOE locus and the pharmacogenetics of lipid response , 2002, Current opinion in lipidology.

[33]  H. Sone,et al.  Sterol regulatory element-binding proteins induce an entire pathway of cholesterol synthesis. , 2001, Biochemical and biophysical research communications.

[34]  J Tuomilehto,et al.  Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study , 2001, BMJ.

[35]  C. Schweiger.  [Statins and the risk of dementia]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[36]  R. Ferrell,et al.  APO E gene and gene-environment effects on plasma lipoprotein-lipid levels. , 2000, Physiological genomics.

[37]  G. Celesia,et al.  Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. , 2000, Archives of neurology.

[38]  E. Corder,et al.  The role of APOE polymorphisms in late-onset dementias , 1998, Cellular and Molecular Life Sciences CMLS.

[39]  L. S. Steijns,et al.  [Apolipoprotein E polymorphism and Alzheimer disease]. , 1996, Tijdschrift voor gerontologie en geriatrie.

[40]  J. Poirier,et al.  Apolipoprotein E, Plaques, Tangles and Cholinergic Dysfunction in Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[41]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[42]  M. Pericak-Vance,et al.  There Is a Pathologic Relationship Between ApoE-ε4 and Alzheimer's Disease-Reply , 1995 .

[43]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[44]  S. Love,et al.  Neurofibrillary tangles in Niemann-Pick disease type C. , 1995, Brain : a journal of neurology.

[45]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[46]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[48]  D. Russell,et al.  Blood cholesterol screening , 1990, The Lancet.

[49]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[50]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[51]  G. Moneta,et al.  Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .

[52]  Nick C Fox,et al.  Letter abstract - Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's Disease , 2009 .

[53]  Qian-Li Xue,et al.  Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study. , 2007, Archives of neurology.

[54]  H. Braak,et al.  Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. , 2003, Archives of neurology.

[55]  F. Pfrieger.  Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes? , 2003, BioEssays : news and reviews in molecular, cellular and developmental biology.

[56]  A. Chait,et al.  Role of ApoE , 2000 .

[57]  M. Pericak-Vance,et al.  There is a pathologic relationship between ApoE-epsilon 4 and Alzheimer's disease. , 1995, Archives of neurology.